The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 01, 2014

Filed:

Feb. 04, 2009
Applicants:

Hiroshi Onogi, Tokyo, JP;

Masatoshi Hagiwara, Chiba, JP;

Masaaki Suzuki, Aichi, JP;

Hiroko Koyama, Gifu, JP;

Takamitsu Hosoya, Kanagawa, JP;

Toshiyuki Hiramatsu, Tokyo, JP;

Inventors:

Hiroshi Onogi, Tokyo, JP;

Masatoshi Hagiwara, Chiba, JP;

Masaaki Suzuki, Aichi, JP;

Hiroko Koyama, Gifu, JP;

Takamitsu Hosoya, Kanagawa, JP;

Toshiyuki Hiramatsu, Tokyo, JP;

Assignee:

Kino Pharma, Inc., Tokyo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 225/02 (2006.01); C07D 401/00 (2006.01); C07D 401/12 (2006.01); A61K 31/395 (2006.01); C07D 213/83 (2006.01); C07D 405/12 (2006.01); A61K 31/55 (2006.01); A61K 31/00 (2006.01); A61K 31/4545 (2006.01); C07D 213/81 (2006.01); A61K 31/455 (2006.01); C07D 213/82 (2006.01); C07D 409/12 (2006.01);
U.S. Cl.
CPC ...
C07D 213/81 (2013.01); A61K 31/395 (2013.01); C07D 213/83 (2013.01); C07D 405/12 (2013.01); A61K 31/55 (2013.01); A61K 31/00 (2013.01); A61K 31/4545 (2013.01); C07D 401/12 (2013.01); A61K 31/455 (2013.01); C07D 225/02 (2013.01); C07D 213/82 (2013.01); C07D 409/12 (2013.01);
Abstract

Viruses, and particularly RNA viruses, have high mutation rates. Hence, antiviral agents that have been developed to date targeting protease or reverse transcriptase of viruses have quickly lost their effectiveness and resistant viruses have emerged. Also, in recent years, viral diseases caused by various new viruses such as SARS, avian influenza, and the hepatitis C have become social menaces. Therefore, the development of a novel antiviral agent that can cope with a virus resistant to an existing drug or a new virus and has a wide range of applications has been demanded. The present invention provides a novel anti-RNA viral agent and a method for use thereof. The present invention further provides an anti-RNA viral agent that is also effective against a new virus or a drug-resistant virus, and a method for use thereof.


Find Patent Forward Citations

Loading…